CareLit · DOI-Nachweis · Klinische Pädiatrie
Toxicity and effectivity of high-dose Idarubicin during AML induction therapy: Results of a pilot study in children
DOI 10.1055/s-2000-9671
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU. Creutzig, D. Körholz, C. M. Niemeyer, H. Kabisch, N. Graf, A. Reiter, H. Scheel-Walter, C. Bender-Götze, W. Behnisch, J. Hermann, G. Mann, J. Ritter, M. Zimmermann
ZeitschriftKlinische Pädiatrie
Ausgabe04/2000
Jahrgang / SeitenJg. 212 · S. 163-168
Kernaussage aus der Literatur
Abstract-Vorschau
Summary. BACKGROUND: Idarubicin (IDR) is one of the most effective, but also toxic drugs in the treatment of AML. The standard dose used in children and adults is 8 - 12 mg/m2 during induction. PATIENTS AND METHODS: To improve outcome, we increased the IDR dose from 12 mg/m2 (standard dose in study AML-BFM 93), applied over three days during induction therapy (AIE=Ara-C, Idarubicin, Etoposide) to 14 mg/m2 in a pilot…
Zitieren
Zitierempfehlung
U. Creutzig, D. Körholz, C. M. Niemeyer, H. Kabisch, N. Graf, A. Reiter, H. Scheel-Walter, C. Bender-Götze, W. Behnisch, J. Hermann, G. Mann, J. Ritter, M. Zimmermann (2000) Toxicity and effectivity of high-dose Idarubicin during AML induction therapy: Results of a pilot study in children. Klinische Pädiatrie, 212 (04), 163-168. https://doi.org/10.1055/s-2000-9671
Mit CareLit weiterarbeiten